DexCom, Inc. (NASDAQ:DXCM) to Post Q2 2024 Earnings of $0.45 Per Share, Leerink Partnrs Forecasts

DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at Leerink Partnrs cut their Q2 2024 earnings per share (EPS) estimates for DexCom in a research note issued on Thursday, April 25th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings of $0.45 per share for the quarter, down from their previous forecast of $0.47. The consensus estimate for DexCom’s current full-year earnings is $1.78 per share. Leerink Partnrs also issued estimates for DexCom’s Q2 2025 earnings at $0.55 EPS, Q4 2025 earnings at $0.73 EPS, FY2025 earnings at $2.24 EPS and FY2028 earnings at $3.74 EPS.

Other equities analysts have also issued research reports about the company. Canaccord Genuity Group raised their price objective on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday. Raymond James raised their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday, April 23rd. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Finally, Citigroup lifted their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $141.67.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $124.34 on Monday. DexCom has a 12 month low of $74.75 and a 12 month high of $142.00. The firm has a market capitalization of $49.24 billion, a P/E ratio of 80.22, a P/E/G ratio of 2.14 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. The company’s fifty day moving average price is $131.13 and its 200 day moving average price is $118.81.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.38%. The company had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million.

Institutional Investors Weigh In On DexCom

Hedge funds and other institutional investors have recently made changes to their positions in the business. DSM Capital Partners LLC acquired a new stake in DexCom in the 4th quarter worth about $28,000. Valley National Advisers Inc. grew its holdings in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. Riverview Trust Co acquired a new position in DexCom during the first quarter worth approximately $32,000. MV Capital Management Inc. increased its position in DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the last quarter. Finally, Smithfield Trust Co boosted its holdings in shares of DexCom by 103.1% in the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after purchasing an additional 165 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 2,624 shares of the stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the sale, the executive vice president now directly owns 68,682 shares in the company, valued at $9,618,227.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the transaction, the executive vice president now owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. In the last three months, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.